Should My Cat Be on Rapamycin or Felycin, and When?

Understanding the Two Paths

It's easy for owners to conflate "rapamycin" and "Felycin" as interchangeable, but the distinction matters clinically:

Felycin-CA1 is a specific sirolimus formulation that has gone through the FDA's conditional approval pathway for a defined indication: feline hypertrophic cardiomyopathy. Conditional approval means the FDA has determined there's a reasonable expectation of effectiveness for this specific use, with full approval pending additional data — it is a real regulatory pathway, distinct from off-label compounding, and specific to this indication.

Compounded rapamycin is sirolimus prepared by a compounding pharmacy at a veterinarian-determined dose, used off-label. This is the pathway used for general longevity purposes in cats without HCM, and historically was also the pathway used for HCM before Felycin-CA1's conditional approval existed.

When HCM Is Already Diagnosed

For a cat with a confirmed HCM diagnosis (via echocardiogram, ideally read by a veterinary cardiologist), the clinical conversation should include:

●        Disease stage and whether the cat is symptomatic or subclinical

●        Whether an HCM-specific, conditionally-approved formulation like Felycin-CA1 is appropriate for that stage

●        Monitoring cadence — echocardiographic recheck intervals, bloodwork

●        How this fits alongside any existing cardiac medications

When There's No HCM Diagnosis

For a cat without a cardiac diagnosis whose owner is interested in general longevity support, the conversation is different — this is a pillar-four longevity decision (see our four-pillar framework), not a disease-specific treatment decision, and should be evaluated on the same candidacy and monitoring basis as any longevity-dosing rapamycin protocol.

Why Real-World Prescribing Experience Matters Here

Regulatory approval and trial data establish that a treatment can work. Real-world prescribing experience — across hundreds of actual clinical cases, with the full range of comorbidities, ages, and disease stages that trials don't always capture — is what tells you how it performs in practice, and what monitoring and dose adjustments actually look like across a large case series. That real-world dataset is central to how longevity protocols are refined at the Pet Longevity Institute. [See our detailed real-world case data analysis on FelycinForCats.com.]

The Bottom Line

The right question isn't "rapamycin or Felycin" as competing options — it's "does my cat have a confirmed HCM diagnosis, and if so, is a conditionally-approved HCM-specific formulation the right fit at this stage." That determination should be made with a veterinarian directly, ideally one with substantial real-world experience prescribing sirolimus in cats specifically.

Frequently Asked Questions

Is Felycin-CA1 the same drug as compounded rapamycin?

The active compound (sirolimus) is the same molecule; Felycin-CA1 is a specific FDA-conditionally-approved formulation for feline HCM, while compounded rapamycin is prepared off-label by a compounding pharmacy for a given indication or dose.

Does my cat need an echocardiogram before starting either option?

For HCM-specific treatment decisions, yes — a confirmed diagnosis and stage assessment (ideally via echocardiogram) should precede treatment choice. For general longevity use without a cardiac diagnosis, candidacy is assessed differently.

How is dosing different between the two?

Dosing should be determined by the prescribing veterinarian based on indication, the cat's weight and health status, and monitoring response — it is not a fixed, one-size-fits-all number for either formulation.

Dr. Kevin Toman, DVM, is the founder of the Pet Longevity Institute and is among the highest-volume real-world prescribers of sirolimus for feline HCM in the United States, with more than 40 years of clinical veterinary experience.